It’s unclear if individual parts of the intervention or the integrated approach itself contributed to improvement over usual ...
Novartis announced that the phase III CV outcomes trial did not meet its primary endpoint, raising doubts over Lp(a)’s role.
The phase II trial didn’t look at MACE, but excitement over inflammation’s role in CVD—and how to tame it—isn’t done yet.
Without reducing death or major bleeding, Toby Rogers says the results can be interpreted based on one’s ‘starting ...
This month, readers gravitated most toward the memory of David Taggart. Stories interpreting data from ESC 2026 also drew ...
While no comparable guidelines exist in the US, Richard Kovacs of the ACC said he considers it to be “eye-opening.” ...
Larger trials with longer follow-up are still needed to cement CSP as an alternative to biventricular pacing, experts say.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results